Home

Keyvisual giving

 

COMPETE.
Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

ITM Radiotheranostics Satellite Symposium.

Prof M Caplin, Prof P Ruszniewski, Dr G Nicolas and Dr S Glasberg discussed about “Towards Optimizing the Application of Radiotheranostics in the Management of NET Patients” at ENETS 2019

Watch the Video >>

Bruce Power, ITM and partners finalize agreement paving way for new medical isotope delivery system expected in 2022

Two partnership agreements signed today will lay the groundwork for a new isotope delivery system at Bruce Power that will help provide lifesaving…

Read more

Press Releases

ITM signs long-term supply agreements with Nordic Nanovector for no-carrier-added Lutetium-177

ITM's subsidiary ITG and Nordic Nanovector have signed long-term global supply agreements for the medical radioisotope n.c.a. 177Lu / EndolucinBeta®…

Read more

Press Releases

ITM erhält Förderbescheid der Bayerischen Forschungsstiftung

Förderung des FORActinium-Projekts durch die Bayerische Forschungsstiftung zur Entwicklung eines Herstellungsverfahrens für das in der zielgerichteten…

Read more

Press Releases

View all news »

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>